BioGaia AB Class B (GB:0GTN)
LSE:0GTN
0GTN Stock Chart & Stats
kr105.70
kr1.00(0.90%)
At close: 4:00 PM EST
kr105.70
kr1.00(0.90%)
Day’s Range― - ―
52-Week Rangekr93.60 - kr136.20
Previous CloseN/A
Volume2.49K
Average Volume (3M)6.59K
Market Cap
kr11.96B
Enterprise Valuekr10.72B
Total Cash (Recent Filing)kr871.78M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)36.0
Beta0.54
Next Earnings
Jul 17, 2026EPS Estimate
1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.28
Shares Outstanding98,497,170
10 Day Avg. Volume4,070
30 Day Avg. Volume6,588
Financial Highlights & Ratios
PEG Ratio-6.22
Price to Book (P/B)8.17
Price to Sales (P/S)6.98
P/FCF Ratio35.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3.98
Revenue Forecast (FY)kr1.66B
Bulls Say, Bears Say
Bulls Say
Proprietary Probiotic Technology And Partner-driven ModelBioGaia's patented Lactobacillus reuteri strains and dual revenue model (own-brand products plus partner supply/licensing) create a durable competitive moat. Partner distribution and licensing scale reach with limited fixed selling cost, supporting repeatable revenue and margin resilience over years.
Recent Top-line Acceleration With High Product MarginsAccelerating revenue alongside very high gross margins suggests strong product economics and pricing power in core probiotic segments. Such structural margin profiles support sustained cash generation, reinvestment in distribution and R&D, and durable competitive positioning versus lower-margin peers.
Very Conservative, Essentially Debt-free Balance SheetNear-zero debt and high returns on equity give BioGaia financial flexibility to fund market expansion, partnerships, and shareholder distributions without refinancing risk. This conservatism reduces downside in stress scenarios and supports long-term strategic optionality.
Bears Say
Multi-year Margin CompressionA sustained decline from 2022 peak margins to current levels indicates structural pressures—mix shifts, higher operating costs or pricing erosion—that could limit long-term profitability. If persistent, this reduces free cash flow and returns available for reinvestment or shareholder payouts.
Declining Equity And Asset Levels From Recent HighsFalling equity and asset bases can reduce the company's capital buffer and its capacity to fund organic growth or strategic investments internally. If driven by distributions over reinvestment, this could constrain long-term expansion or increase reliance on external funding for larger initiatives.
Inconsistent Cash Conversion And Working-capital HeadwindsWhile FCF roughly tracks earnings, weakening cash coverage and lower FCF conversion versus prior year point to working-capital swings. This variability undermines predictability of internally generated funds for capex, partnerships, or dividends, increasing operational financing risk.
BioGaia AB News
0GTN FAQ
What was BioGaia AB Class B’s price range in the past 12 months?
BioGaia AB Class B lowest share price was kr93.60 and its highest was kr136.20 in the past 12 months.
What is BioGaia AB Class B’s market cap?
BioGaia AB Class B’s market cap is kr11.96B.
When is BioGaia AB Class B’s upcoming earnings report date?
BioGaia AB Class B’s upcoming earnings report date is Jul 17, 2026 which is in 27 days.
How were BioGaia AB Class B’s earnings last quarter?
BioGaia AB Class B released its earnings results on May 13, 2026. The company reported kr0.78 earnings per share for the quarter, beating the consensus estimate of kr0.777 by kr0.003.
Is BioGaia AB Class B overvalued?
According to Wall Street analysts BioGaia AB Class B’s price is currently Overvalued.
Does BioGaia AB Class B pay dividends?
BioGaia AB Class B does not currently pay dividends.
What is BioGaia AB Class B’s EPS estimate?
BioGaia AB Class B’s EPS estimate is 1.08.
How many shares outstanding does BioGaia AB Class B have?
BioGaia AB Class B has 98,497,170 shares outstanding.
What happened to BioGaia AB Class B’s price movement after its last earnings report?
BioGaia AB Class B reported an EPS of kr0.78 in its last earnings report, beating expectations of kr0.777. Following the earnings report the stock price went up 0.495%.
Which hedge fund is a major shareholder of BioGaia AB Class B?
Currently, no hedge funds are holding shares in GB:0GTN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioGaia AB Class B
BioGaia AB (publ), a Swedish enterprise founded in 1990 and headquartered in Stockholm, is dedicated to the worldwide development, marketing, and distribution of probiotic products renowned for their scientifically proven health advantages. The company operates through three primary divisions. Its Pediatrics segment offers various items such as drops, oral rehydration solutions, and gut health tablets, in addition to supplying cultures for integration into infant formula. The Adult Health segment provides gut health tablets and oral health lozenges, alongside furnishing cultures to licensees for use in dairy products. A third segment, "Other," specializes in packaging solutions. BioGaia's extensive product portfolio targets a range of health issues, including infantile colic and digestive health in children, antibiotic-associated and acute diarrhea, gingivitis, periodontal disease, general well-being, Helicobacter pylori bacterial infections (linked to gastric ulcers), and concerns related to low bone density. All of its offerings are sold exclusively under the BioGaia brand.
Technical Analysis
Options Prices
Currently, No data available
---